DGX241115C160000
- 1.77
- +1.72+3440.00%
Quest Diagnostics Newsroom
Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Equillium (EQ), Quest Diagnostics (DGX) and Alnylam Pharma (ALNY)
Quest Diagnostics Analyst Ratings
Piper Sandler Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165
Piper Sandler Reaffirms Their Hold Rating on Quest Diagnostics (DGX)
Jefferies Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $175
Quest Diagnostics (DGX) Receives a Buy From Jefferies
Argus Research Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $175
Quest Diagnostics: Balanced Risk and Reward Justifies Hold Rating Amid Growth and Margin Challenges
A Quick Look at Today's Ratings for Quest Diagnostics(DGX.US), With a Forecast Between $165 to $185
Quest Upgraded to Outperform by Baird, Sector Momentum Cited
Quest Diagnostics Is Maintained at Buy by Citigroup
A Quick Look at Today's Ratings for Quest Diagnostics(DGX.US), With a Forecast Between $165 to $185
UBS Adjusts Price Target on Quest Diagnostics to $166 From $165, Maintains Neutral Rating
Evercore ISI Sticks to Its Hold Rating for Quest Diagnostics (DGX)
Quest Diagnostics Analyst Ratings
Quest Diagnostics: Resilient Growth Prospects Amid Challenges Support Buy Rating
Quest Diagnostics Upgraded to Outperform From Neutral at Baird
Quest Diagnostics (DGX) Gets a Hold From Barclays
UBS Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165